When sales trail a label expansion, test the forecasting method before concluding that the market has underdelivered.
An emerging cardiometabolic biopharma faced a critical question after a label expansion increased the eligible patient population, yet sales growth lagged expectations. Rather than assuming the market had underperformed, the company reevaluated its forecasting approach.
Discover how a machine learning-driven forecasting framework helped separate the impact of the label expansion from underlying market dynamics, delivering a more accurate and actionable view of future demand.
What This Case Study Will Show You
- Why a post-expansion sales gap calls for testing the forecast before blaming the market
- How the label expansion’s impact was separated from underlying demand
- How model choice was settled by a measurable error score, with no room for subjective preference
- What approximately 25% higher forecast accuracy looked like across the brand portfolio
- How the forecast now runs on a repeatable cycle with minimal manual intervention
“Forecasts now reflect real-world market performance instead of aging analog assumptions.”
- From the case study
Built For
- Forecasting and Demand Planning Leaders
- Commercial analytics leaders
- Launch and Lifecycle Planning Teams
- Emerging Biopharma Organizations
- Commercial Operations and Business Planning Leaders
FAQs
